

# COVID-19 outcomes in hospitalized puerperal, pregnant, and neither pregnant nor puerperal women: a population study

Fabiano Elisei Serra<sup>1</sup>, Rossana Pulcineli Vieira Francisco<sup>1\*</sup>, Patricia de Rossi<sup>2,3</sup>, Maria de Lourdes  
Brizot<sup>1</sup>, Agatha Sacramento Rodrigues<sup>1,4\*</sup>

<sup>1</sup>Disciplina de Obstetrícia, Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina da  
Universidade de São Paulo, São Paulo, São Paulo, Brazil

<sup>2</sup>Curso de Medicina, Universidade de Santo Amaro (UNISA), São Paulo, São Paulo, Brazil

<sup>3</sup>Gerência de Medicina Perinatal e Ginecologia, Conjunto Hospitalar do Mandaqui, São Paulo, São  
Paulo, Brazil

<sup>4</sup>Departamento de Estatística, Universidade Federal do Espírito Santo, Vitória, Espírito Santo, Brazil

\* Corresponding author

E-mail: [agatha.rodrigues@ufes.br](mailto:agatha.rodrigues@ufes.br) (ASR)

## Abstract

**Objective** To compare hospitalized reproductive age women with COVID-19 who were pregnant, puerperal, or neither one nor the other in terms of demographic and clinical characteristics and disease progression using Brazilian epidemiological data.

**Methods** A retrospective analysis of the records of the Information System of the Epidemiological Surveillance of Influenza of the Health Ministry of Brazil was performed. It included the data of female patients aged 10 to 49 years hospitalized because of severe COVID-19 disease (RT-PCR+ for SARS-CoV-2), from February 17, 2020 to January 02, 2021. They were separated into 3 groups: pregnant, puerperal, and neither pregnant nor puerperal. General comparisons and then adjustments for confounding variables (propensity score matching [PSM]) were made, using demographic and clinical characteristics, disease progression (admission to the intensive care unit [ICU] and invasive or noninvasive ventilatory support), and outcome (cure or death). Deaths were analyzed in each group according to comorbidities, invasive or noninvasive ventilatory support, and admission to the ICU.

**Results** As many as 40,640 reproductive age women hospitalized for COVID-19 were identified: 3,372 were pregnant, 794 were puerperal, and 36,474 were neither pregnant nor puerperal. Groups were significantly different in terms of demographic data and comorbidities. Pregnant and puerperal women were less likely to be symptomatic than the women who were neither one nor the other. Pregnant women, however, had a higher frequency of cough, anosmia, and ageusia. Puerperal women had a worse prognosis than pregnant women with respect to admission to the ICU, invasive ventilatory support, and death.

**Conclusion** Puerperal women were at a higher risk for serious outcomes (need for the ICU, need for invasive and noninvasive ventilatory support, and death) than pregnant women.

## Introduction

COVID-19 is an infectious disease caused by the new coronavirus (SARS-CoV-2), and it has a clinical spectrum ranging from absence of symptoms to severe illness and death. Widespread contagion

and the ability of the virus to disseminate led the World Health Organization (WHO) to declare a pandemic state in March 2020 [1]. The high incidence has had a tremendous socioeconomic impact worldwide. One day prior to the submission of this article (June 28, 2021), globally, there were more than 180 million confirmed cases of COVID-19 and 3,923,238 deaths [2].

Since the beginning of the pandemic, the infection has been studied in the obstetric population to understand its consequences and to prevent adverse maternal-fetal outcomes. The initial publications describing COVID-19 cases in pregnant women in China, Europe, and North America did not report increased severity and deaths compared to the general population [3-9]. Subsequent studies, however, showed a higher likelihood of the need for admission to intensive care units (ICUs) and mechanical ventilation [10-14]. The first maternal deaths were reported in the United Kingdom, Iran, United States, Mexico, and France [15-19]. In Brazil, the high number of maternal deaths due to COVID-19 has been attributed to factors such as high birth rate, poor nutrition and health, difficult access to health services, and insufficient obstetric assistance [20,21].

Socioeconomic heterogeneity in Brazil is reflected in the quality of health services and in the availability of hospital and ICU beds, having a great impact on health indicators of both pregnant and puerperal women [22,23]. Understanding the disease and evaluating why the prognoses of pregnant and puerperal women have been worse in this pandemic is relevant. We did not find any studies comparing demographic and clinical characteristics and disease progression among pregnant women, puerperal women, and neither pregnant nor puerperal women hospitalized with COVID-19. Therefore, the authors of the present study aim to compare pregnant women, puerperal women, and neither pregnant nor puerperal women according to data related to the SARS-CoV-2 infection by using population statistics from SIVEP-Gripe (System of Information about Epidemiological Surveillance of Influenza) of the Health Ministry of Brazil.

## Materials and methods

A retrospective analysis of the statistics from SIVEP-Gripe, a Brazilian national database containing surveillance data on severe acute respiratory syndrome (SARS) was performed [24]. The notification of SARS is compulsory in cases of the flu syndrome (acute respiratory condition, characterized by at least two of the following signs and symptoms: fever [even if reported], chills, sore throat, headache, cough, coryza, and disorders of taste or smell), accompanied by dyspnea/respiratory distress, persistent chest pressure, oxygen saturation (SpO<sub>2</sub>) below 95% in room air, or cyanosis. The SIVEP-Gripe is notified of all cases of hospitalization both in public and in private hospitals, as well as of all deaths caused by SARS-CoV-2, irrespective of hospitalization.

SIVEP-Gripe records include the following: demographic data (sex, age, skin color/ethnicity, obstetric status, schooling, city of residence); clinical data (signs and symptoms, risk factors/comorbidities); epidemiological data (previous flu vaccination, community-acquired infection, or nosocomial infection); laboratory and etiological diagnoses. There is also information about hospital admission, ICU admission, use of ventilatory support (invasive and noninvasive), and disease outcome (cure or death).

Data search covered epidemiological weeks 1 to 53 (December 29, 2019 - January 02, 2021), with the last update on January 11, 2021; however, the first Brazilian records began in epidemiological week 8 (first day of symptoms of the first confirmed case was on February 17, 2020). Search included all data on female patients aged 10 to 49 years hospitalized with COVID-19, confirmed with a positive RT-PCR result for SARS-CoV-2. Cases were excluded if they were unhospitalized or unconfirmed with an RT-PCR for SARS-CoV-2, or if gender or pregnancy status were not recorded. The result was 40,640 women hospitalized with COVID-19 (RT-PCR+) and aged between 10 and 49 years, who were divided into two groups: pregnant women (n=3,372) and nonpregnant women

(n=37,268). The latter were separated into puerperal (n=794) and neither pregnant nor puerperal (n=36,474) (Figure 1).

Variables used in the analysis were age, pregnancy status, comorbidities, schooling, skin color/ethnicity, signs and symptoms, SARI (Severe Acute Respiratory Infection, defined as temperature  $\geq 38^{\circ}\text{C}$ , cough, and onset in 10 days), SARI without fever, admission to ICU, respiratory support, and outcome (cure or death). Comorbidities reported were chronic cardiovascular, renal, neurological, hematologic, hepatic, and respiratory diseases, asthma, obesity, diabetes, and immunosuppression. Fever, cough, sore throat, dyspnea, respiratory discomfort,  $\text{SpO}_2 < 95\%$ , diarrhea, vomiting, abdominal pain, fatigue, anosmia, and ageusia were the signs and symptoms.

Deaths were analyzed individually according to comorbidities, invasive and noninvasive respiratory support, and admission to ICU.

SIVEP-Gripe records are publicly available anonymized data. Therefore, according to Brazilian Ethics regulatory requirements, there is no need for ethical approval by an Institutional Review Board.

## Data analysis

Quantitative variables were summarized as mean and standard deviation. Qualitative variables were displayed as absolute frequencies (n) and category percentages (%).

Nonparametric Kruskal-Wallis test was applied to compare the three study groups in terms of quantitative variables. Chi-square test was used to evaluate the association between groups and qualitative variables. Odds Ratio (OR) was considered as a measure of association to compare the relative odds of the occurrence of the outcome of interest with a 95% confidence interval (95%CI).

Propensity score matching (PSM) was used to create weights for the observations to make the three study groups equivalent in relation to the confounding variables [25]. The first analysis, used

to compare the symptoms between groups, included age, ethnicity, chronic cardiovascular disease, asthma, diabetes, immunosuppression, and obesity. The second one, comparing the outcomes, included the same variables plus schooling, Federative Unit of Brazil, and respiratory symptoms. The analyses were performed with the statistical R software (R Foundation for Statistical Computing Platform, version 4.0.3) [26] and PSM was carried out with the R WeightIt package [27].

## Results

A total of 40,640 reproductive age women hospitalized with a positive RT-PCR for SARS-CoV-2 result were identified. Of these, 3,372 were pregnant and 37,268 were not pregnant (Figure 1). Nonpregnant women comprised 794 puerperal women and 36,474 women who were neither pregnant nor puerperal. Groups differed significantly related to demographic data and comorbidities (Table 1). The group of neither pregnant nor puerperal women had the highest rate of comorbidities.

### Figure 1: Study profile

**Table 1. Demographic and clinical characteristics of reproductive age women with COVID-19 according to gestational status – Brazil, February 17, 2020 – January 02, 2021**

Characteristics	Neither pregnant nor puerperal	Pregnant	Puerperal	p
<b>Age (years)</b>				
Mean ± SD	38.22 ± 8.25	29.64 ± 6.93	30.24 ± 7.34	<0.0001
<b>Age bracket (years)</b>	<b>n (%)</b>	<b>n (%)</b>	<b>n (%)</b>	
<20	1,009 (2.8)	250 (7.4)	61 (7.7)	<0.0001
20-34	9,629 (26.4)	2,244 (66.5)	494 (62.2)	
>34	2,5836 (70.8)	878 (26.0)	239 (30.1)	
Total	36,474	3,372	794	
<b>Skin color/Ethnicity</b>	<b>n (%)</b>	<b>n (%)</b>	<b>n (%)</b>	
White	15,418 (54.0)	1,102 (40.5)	238 (37.2)	<0.0001
Black	1,679 (5.9)	192 (7.1)	46 (7.2)	

<b>Yellow</b>	359 (1.3)	33 (1.2)	4 (0.6)	
<b>Brown</b>	10,976 (38.5)	1,382 (50.8)	348 (54.4)	
<b>Indigenous</b>	97 (0.3)	13 (0.5)	4 (0.6)	
<b>Total</b>	28,529 (100)	2,722 (100)	640 (100)	
<b>Schooling</b>	<b>n (%)</b>	<b>n (%)</b>	<b>n (%)</b>	
<b>No schooling</b>	219 (1.4)	7 (0.5)	2 (0.6)	
<b>Up to high school</b>	3,661 (23.7)	360 (25.1)	81 (24.5)	<0.0001
<b>High school</b>	7,532 (48.7)	790 (55.1)	179 (54.2)	
<b>College</b>	4,058 (26.2)	277 (19.3)	68 (20.6)	
<b>Total</b>	15,470 (100)	1,434 (100)	330 (100)	
<b>Risk factors and comorbidities</b>	<b>n (%)</b>	<b>n (%)</b>	<b>n (%)</b>	
<b>Chronic cardiovascular disease (n=14,976)</b>	5780/13,330 (43.4)	214/1,141 (18.8)	77/505 (15.2)	<0.0001
<b>Chronic hematologic disease (n=12,901)</b>	356/11,340 (3.1)	16/1,081 (1.5)	11/480 (2.3)	0.006
<b>Chronic hepatic disease (n=12,769)</b>	189/11,226 (1.7)	8/1,066 (0.8)	4/477 (0.8)	0.0273
<b>Asthma (n=13,426)</b>	1883/11,821 (15.9)	139/1,119 (12.4)	33/486 (6.8)	<0.0001
<b>Diabetes (n=14,575)</b>	4825/12,934 (37.3)	241/1,151 (20.9)	61/490 (12.4)	<0.0001
<b>Chronic neurological disease (n=12,933)</b>	568/11,377 (5.0)	25/1,078 (2.3)	5/478 (1.0)	<0.0001
<b>Chronic lung disease (n=12,945)</b>	579/11,390 (5.1)	23/1,075 (2.1)	5/480 (1.0)	<0.0001
<b>Immunodepression (n=13,137)</b>	1,289/11,578 (11.1)	40/1,078 (3.7)	18/481 (3.7)	<0.0001
<b>Chronic renal disease (n=13,047)</b>	1,080/11,495 (9.4)	24/1,073 (2.2)	12/479 (2.5)	<0.0001
<b>Obesity (n=13,713)</b>	3,741/12,135 (30.8)	143/1,097 (13.0)	53/481 (11.0)	<0.0001
<b>Metabolic syndrome (n=12,509)</b>	422/10,998 (3.8)	7/1,044 (0.7)	7/467 (1.5)	<0.0001
<b>Number of comorbidities (n=11,958)</b>	<b>n (%)</b>	<b>n (%)</b>	<b>n (%)</b>	<b>&lt; 0.0001</b>
<b>0</b>	2,022/10,502 (19.3)	576/999 (57.7)	335/457 (73.3)	
<b>1-2</b>	7,681/10,502 (73.1)	408/999 (40.8)	106/457 (23.2)	
<b>&gt;2</b>	799/10,502 (7.6)	15/999 (1.5)	16/457 (3.5)	

132

133

134 Table 2 shows the results of the comparison of COVID-19 symptoms before and after PSM in the  
135 three study groups. Both pregnant and puerperal women had a smaller chance of fever, cough, sore  
136 throat, dyspnea, respiratory discomfort, SpO<sub>2</sub><95%, diarrhea, vomiting, fatigue, SARI, and SARI  
137 without fever than neither pregnant nor puerperal women. Pregnant women had anosmia and  
138 ageusia more frequently than the others. Puerperal women had fewer chance of fever, coughing,  
139 vomiting, SARI, and SARI without fever than pregnant women; however, their oxygen saturation  
140 level was more frequently lower than 95% at hospital admission.

**Table 2. COVID-19 signs, symptoms, and infection in pregnant, puerperal, and neither pregnant nor puerperal reproductive age women before and after propensity score matching – Brazil, February 17, 2020 – January 02, 2021**

Signs, symptoms, and infection	Neither pregnant nor puerperal	Pregnant	Puerperal	Group comparison			Group comparison after PSM (age + ethnicity + cardiopathy + asthma + diabetes + immunosuppression + obesity)		
	n (%)	n (%)	n (%)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)
Fever (n=36,371)	24,297/32,702 (74.3)	2,038/2,983 (68.3)	424/686 (61.8)	0.75 (0.69 – 0.81)	0.56 (0.48 – 0.65)	0.75 (0.63 – 0.89)	0.78 (0.69 – 0.88)	0.63 (0.53 – 0.74)	0.81 (0.67 – 0.93)
Cough (n=37,101)	27,305/33,324 (81.9)	2,408/3,085 (78.1)	475/692 (68.6)	0.78 (0.72 – 0.86)	0.48 (0.41 – 0.57)	0.62 (0.51 – 0.74)	1.19 (1.04 – 1.36)	0.81 (0.67 – 0.97)	0.68 (0.56 – 0.82)
Sore throat (n=31,474)	8,854/28,242 (31.4)	724/2,629 (27.5)	156/603 (25.9)	0.83 (0.76 – 0.91)	0.76 (0.63 – 0.92)	0.92 (0.75 – 1.12)	0.88 (0.78 – 1.01)	0.90 (0.74 – 1.10)	1.02 (0.83 – 1.26)
Dyspnea (n=36,272)	25,134/32,664 (76.9)	1,761/2,940 (59.9)	381/668 (57.0)	0.45 (0.41 – 0.48)	0.40 (0.34 – 0.47)	0.89 (0.75 – 1.05)	0.54 (0.48 – 0.61)	0.54 (0.45 – 0.64)	1.00 (0.84 – 1.20)
Respiratory discomfort (n=34,023)	20,158/30,600 (65.9)	1,374/2,771 (49.6)	341/652 (52.3)	0.51 (0.47 – 0.55)	0.57 (0.49 – 0.66)	1.11 (0.94 – 1.32)	0.60 (0.54 – 0.68)	0.73 (0.62 – 0.87)	1.21 (1.02 – 1.45)
SpO <sub>2</sub> < 95% (n=33,482)	17,109/30,137 (56.8)	860/2,708 (31.8)	291/637 (45.7)	0.35 (0.32 – 0.39)	0.64 (0.55 – 0.75)	1.81 (1.52 – 2.15)	0.40 (0.35 – 0.45)	0.79 (0.67 – 0.94)	1.99 (1.65 – 2.39)
At least 1 respiratory symptom (n=37,726)	30,208/34,002 (88.8)	2,177/3,021 (72.1)	490/703 (69.7)	0.32 (0.30 – 0.35)	0.29 (0.25 – 0.34)	0.89 (0.75 – 1.07)	0.44 (0.38 – 0.51)	0.43 (0.36 – 0.53)	0.98 (0.81 – 1.18)
Diarrhea (n=30,907)	6,387/27,758 (23.0)	335/2,574 (13.0)	65/575 (11.3)	0.50 (0.44 – 0.56)	0.43 (0.33 – 0.55)	0.85 (0.64 – 1.13)	0.61 (0.52 – 0.71)	0.53 (0.41 – 0.70)	0.88 (0.66 – 1.18)
Vomiting (n=30,342)	4,148/27,206 (15.2)	342/2,566 (13.3)	45/570 (7.9)	0.86 (0.76 – 0.96)	0.48 (0.35 – 0.64)	0.56 (0.40 – 0.77)	0.75 (0.63 – 0.89)	0.47 (0.34 – 0.64)	0.63 (0.45 – 0.87)
Abdominal pain (n=15,775)	13,47/14,360 (9.4)	117/1,175 (10.0)	20/240 (8.3)	1.07 (0.87 – 1.30)	0.88 (0.54 – 1.37)	0.83 (0.49 – 1.33)	0.94 (0.69 – 1.28)	0.75 (0.45 – 1.24)	0.80 (0.48 – 1.33)
Fatigue (n=16,216)	4,383/14,780 (29.7)	263/1,191 (22.1)	47/245 (19.2)	0.67 (0.58 – 0.77)	0.56 (0.41 – 0.77)	0.84 (0.59 – 1.18)	0.95 (0.78 – 1.15)	0.86 (0.61 – 1.20)	0.90 (0.63 – 1.29)
Anosmia (n=16,202)	3,216/14,718 (21.9)	335/1,224 (27.4)	51/260 (19.6)	1.35 (1.18 – 1.54)	0.87 (0.64 – 1.18)	0.65 (0.46 – 0.90)	1.79 (1.48 – 2.17)	1.26 (0.91 – 1.75)	0.70 (0.50 – 0.99)
Ageusia (n=16,103)	3,121/14,634 (21.3)	297/1,212 (24.5)	45/257 (17.5)	1.20 (1.04 – 1.37)	0.79 (0.56 – 1.08)	0.66 (0.46 – 0.92)	1.70 (1.41 – 2.04)	1.17 (0.84 – 1.64)	0.69 (0.48 – 0.99)
SARI (n=34,118)	18,089/30,689 (58.9)	1,308/2,795 (46.8)	242/634 (38.2)	0.61 (0.57 – 0.66)	0.43 (0.37 – 0.51)	0.70 (0.59 – 0.84)	0.78 (0.70 – 0.88)	0.58 (0.49 – 0.69)	0.74 (0.62 – 0.89)
SARI without fever (n=35,939)	24,504/32,353 (75.7)	1,816/2,925 (62.1)	351/661 (53.1)	0.52 (0.48 – 0.57)	0.36 (0.31 – 0.42)	0.69 (0.58 – 0.82)	0.75 (0.67 – 0.85)	0.57 (0.48 – 0.67)	0.75 (0.63 – 0.90)
Hospital-acquired infection (n=30,722)	760/27,508 (2.8)	37/2,617 (1.4)	34/597 (5.7)	0.51 (0.36 – 0.70)	2.13 (1.47 – 2.99)	4.21 (2.61 – 6.78)	0.38 (0.24 – 0.59)	1.28 (0.85 – 1.93)	3.38 (2.01 – 5.69)

PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%CI, 95% confidence interval; SpO<sub>2</sub>, oxygen saturation in room air; SARI, temperature ≥ 38°C, cough, and onset in 10 days



A remarkable fact related to hospital-acquired COVID-19 is that pregnant women developed the disease less frequently (1.4%) than neither pregnant nor puerperal women (2.8%) and puerperal women (5.7%).

A PSM analysis of the statistical differences between the groups, especially regarding age, skin color/ethnicity, and comorbidities, showed that pregnant women had cough more frequently than neither pregnant nor puerperal women. Sore throat and fatigue did not differ significantly between the groups. The remainder of the PSM analysis comparing pregnant and puerperal women with neither pregnant nor puerperal yielded similar results to the general analysis. When comparing puerperal to pregnant women, the only difference was a higher frequency of respiratory discomfort in the first group.

Pregnant, compared to neither pregnant nor puerperal women, were less likely to have any of the study outcomes (admission to ICU, invasive and noninvasive respiratory support, and death). On the other hand, puerperal women, when contrasted with neither pregnant nor puerperal, were more likely to be admitted to the ICU and less likely to need noninvasive support. Puerperal had a higher risk of needing admission to the ICU, requiring invasive respiratory support, and dying, than pregnant women (Table 3).

**Table 3. Comparison of outcomes in pregnant, puerperal, and neither pregnant nor puerperal reproductive age women before and after propensity score matching– Brazil, February 17, 2020 – January 02, 2021**

Outcome	Neither pregnant nor puerperal	Pregnant	Puerperal	Group comparison			Group comparison after PSM (age + ethnicity + schooling + FUB + chronic cardiovascular disease + asthma + diabetes + immunosuppression + obesity + respiratory symptoms)		
	n (%)	n (%)	n (%)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)

						CI)	CI)	CI)	CI)
<b>ICU admission (n=32,769)</b>	8014/29,36 8 (27.3)	574/2,72 1 (21.1)	244/680 (35.9)	0.71 (0.65 – 0.78)	1.49 (1.27 – 1.75)	2.09 (1.74 – 2.51)	0.58 (0.48 – 0.71)	1.14 (0.91 – 1.43)	1.97 (1.62 – 2.40)
<b>Ventilato ry support (n=31,45 7)</b>	<b>No</b> n=28,199	<b>Yes, invasive</b> n=2,598	<b>Yes, noninvas ive</b> n=660						
	3,536 (12.5)	209 (8.0)	133 (20.2)	0.42 (0.36 - 0.48)	1.23 (1.00 – 1.51)	2.96 (2.31 – 3.79)	0.48 (0.33 - 0.68)	1.29 (0.96 - 1.74)	2.71 (1.91 - 3.82)
	13,213 (46.9)	763 (29.4)	178 (27.0)	0.41 (0.37 – 0.44)	0.44 (0.37 – 0.53)	1.09 (0.89 – 1.33)	0.59 (0.47 - 0.75)	0.65 (0.51 - 0.83)	1.10 (0.86 - 1.42)
<b>Death (n=35,700)</b>	4,534/32,0 81 (14.1)	181/2,90 4 (6.2)	114/715 (15.9)	0.40 (0.34 – 0.47)	1.15 (0.94 – 1.41)	2.85 (2.22 – 3.66)	0.43 (0.34 – 0.54)	1.09 (0.86 – 1.38)	2.51 (1.90 – 3.31)

PSM, Propensity Score Matching; NPRNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%CI, 95% confidence interval; FUB, Federative Unit of Brazil; ICU, Intensive Care Unit

After PSM (with the inclusion schooling, Federative Unit of Brazil, and respiratory symptoms variables), the only difference between this analysis and the general analysis was that puerperal women were no longer more likely than neither pregnant nor puerperal women to be admitted to ICU, while maintaining a worse prognosis than that of pregnant women with respect to admission to the ICU, invasive ventilatory support, and death.

Pregnant women with chronic cardiovascular or renal disease, asthma, diabetes, immunodepression, or obesity, and those in the ICU, or those who received ventilatory support were less likely to die than neither pregnant nor puerperal women with the same characteristics (Table 4). Puerperal women did not differ significantly from neither pregnant nor puerperal regarding the study variables. Puerperal women had a greater likelihood of dying than pregnant women when both had asthma, diabetes, or obesity, or when received noninvasive ventilatory support, or were admitted to the ICU. After PSM, of women with chronic cardiovascular disease or diabetes and of those admitted to ICU or who received noninvasive support, pregnant were less likely to die than neither pregnant nor puerperal women.

**Table 4. Comparison of the death rates of pregnant, puerperal, and neither pregnant nor puerperal reproductive age women before and after propensity score matching according to comorbidities, ICU admission, and ventilatory support – Brazil, February 17, 2020 – January 02, 2021**

Variable	Death rate			Group comparison			Group comparison after PSM (age + ethnicity + schooling + FUB + chronic cardiovascular disease + asthma + diabetes + immunosuppression + obesity + respiratory symptoms)		
	Neither pregnant nor puerperal	Pregnant	Puerperal	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)
Chronic cardiovascular disease (n=5,349)	1,159/5,093 (22.8)	24/186 (12.9)	15/70 (21.4)	0.51 (0.32 – 0.77)	0.93 (0.51 – 1.62)	1.84 (0.88 – 3.75)	0.47 (0.28 – 0.79)	0.96 (0.52 – 1.75)	2.02 (0.97 – 4.24)
Asthma (n=1,804)	254/1,658 (15.3)	8/119 (6.7)	6/27 (22.2)	0.41 (0.18 – 0.79)	1.61 (0.58 – 3.82)	3.93 (1.16 – 12.75)	0.56 (0.20 – 1.59)	2.68 (0.99 – 7.20)	4.79 (1.27 – 18.02)
Diabetes (n=4,539)	1,143/4,268 (26.8)	27/212 (12.7)	19/59 (32.2)	0.40 (0.26 – 0.59)	1.30 (0.73 – 2.23)	3.24 (1.62 – 6.41)	0.43 (0.26 – 0.72)	1.52 (0.85 – 2.70)	3.50 (1.70 – 7.22)
Immunodepression (n=1,213)	408/1,159 (35.2)	6/36 (16.7)	3/18 (16.7)	0.38 (0.14 – 0.85)	0.38 (0.08 – 1.18)	1.02 (0.18 – 4.62)	0.54 (0.19 – 1.48)	0.55 (0.15 – 1.98)	1.03 (0.21 – 5.01)
Chronic Renal disease (n=995)	385/963 (40.0)	2/21 (9.5)	4/11 (36.4)	0.17 (0.02 – 0.59)	0.87 (0.22 – 2.98)	4.96 (0.74 – 47.5)	0.59 (0.12 – 2.82)	1.52 (0.41 – 5.65)	2.56 (0.37 – 17.61)
Obesity (n= 3,500)	762/3,327 (22.9)	19/125 (15.2)	15/48 (31.2)	0.61 (0.36 – 0.97)	1.54 (0.80 – 2.80)	2.52 (1.14 – 5.55)	0.80 (0.42 – 1.53)	2.29 (1.22 – 4.30)	2.84 (1.19 – 6.78)
Invasive respiratory support (n=3,878)	2,249/3,536 (63.6)	104/209 (49.8)	77/133 (57.9)	0.57 (0.43 – 0.75)	0.79 (0.55 – 1.12)	1.39 (0.89 – 2.16)	0.68 (0.38 – 1.21)	0.83 (0.46 – 1.48)	1.22 (0.75 – 1.99)
Noninvasive respiratory support (n=14,154)	1246/13,213 (9.4)	37/763 (4.8)	18/178 (10.1)	0.49 (0.35 – 0.69)	1.09 (0.64 – 1.73)	2.21 (1.20 – 3.95)	0.48 (0.30 – 0.77)	0.92 (0.53 – 1.60)	1.93 (1.02 – 3.63)
ICU admission (n=8,832)	2,755/8,014 (34.4)	127/574 (22.1)	90/244 (36.9)	0.54 (0.44 – 0.66)	1.12 (0.85 – 1.45)	2.06 (1.48 – 2.85)	0.69 (0.48 – 0.99)	1.27 (0.88 – 1.83)	1.84 (1.28 – 2.64)

PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%CI, 95% confidence interval; FUB, Federative Unit of Brazil; ICU, Intensive Care Unit

## Discussion

The results of the current analysis show that at hospital admission, both pregnant and puerperal women, in general, presented a lower rate of symptoms than neither pregnant nor puerperal women, except for cough, anosmia, and ageusia of pregnant women. On the other hand, the

contrast between puerperal and pregnant women revealed that the former had a higher rate of respiratory discomfort and  $SpO_2 < 95\%$ , as well as a higher likelihood of ICU admission, invasive ventilatory support, and death. Therefore, our study data suggest that puerperal women are at a higher risk of severe outcomes than pregnant women and run as much risk as neither pregnant nor puerperal women.

At the beginning of the COVID-19 pandemic, the initial publications addressing infections in pregnant women were case reports, short case series, and systematic reviews. Given the low case numbers, the first impression was that pregnant and puerperal women were not at a higher risk for complications and death than the non-obstetric population [3-9]. As epidemiological weeks passed, new studies reported a greater need for invasive ventilation and ICU and an increased number of deaths in the obstetric population [10,11,13,14,16,28].

The United States Centers for Disease Control and Prevention published data from January 22 to October 3, 2020, comprising 1,300,938 women with COVID-19. Of these, 23,434 were symptomatic pregnant women. In that study, pregnant women, as opposed to nonpregnant, ran a higher risk of ICU admission, invasive ventilation, extracorporeal membrane oxygenation (ECMO), and death [13]. In our study, the sample included only hospitalized women with SARS-CoV-2. After PSM, our results differed from the CDC results as follows: pregnant women were less likely to be admitted to an ICU (OR 0.58), to need invasive ventilation (OR 0.48), or to die (OR 0.43) than nonpregnant; however, puerperal women were at a higher risk of death than pregnant women. Among all the signs and symptoms reported in the CDC study, cough, headache, myalgia, and fever were the most common and they were mostly reported by the nonpregnant women [13]. Our data also show that the most common signs and symptoms in all groups were cough, dyspnea, and fever, with both pregnant and puerperal women showing fewer symptoms than nonpregnant women. Nevertheless,

222 pregnant women had anosmia and dysgeusia significantly more frequently than the other two  
223 groups.

224 In a study with the Brazilian population involving 2,475 pregnant and puerperal women with SARS,  
225 72% of whom had COVID-19 confirmed by RT-PCR, 590 had unfavorable outcomes. The risk  
226 increased 2.4 times when the SARS notification occurred in the postpartum period rather than  
227 during pregnancy [21]. In the present study, all cases were confirmed by RT-PCR, and the  
228 unfavorable outcomes (ICU, mechanical ventilation, and death) were analyzed separately for each  
229 group of women (pregnant, puerperal, and neither pregnant nor puerperal) to identify the specific  
230 risks for each outcome and each group. After pairing with PSM, puerperal women were more likely  
231 than pregnant women to be admitted to ICU (OR 1.97), to receive invasive respiratory support (OR  
232 2.71), to die (OR 2.51), and to acquire the COVID-19 infection in hospital (OR 3.38).

233 In Mexico, a study including a cohort of 5,183 pregnant women and 175,905 nonpregnant women  
234 with COVID-19 compared the two groups regarding death, pneumonia, invasive respiratory  
235 support, and ICU admission. The data (comorbidities, age, language, and health insurance level)  
236 were analyzed with and without adjustment for propensity score matching. After pairing, pregnant  
237 women showed a higher likelihood of death (OR 1.84), pneumonia (OR 1.86), and ICU admission  
238 (OR 1.86) than nonpregnant, but both groups ran a similar risk of invasive respiratory support (OR  
239 0.93) [14]. The study, however, did not evaluate either group separately. In contrast to the Mexican  
240 study, our data, following adjustments, revealed that pregnant women had a lower likelihood of  
241 death (OR 0.43), invasive respiratory support (OR 0.48), and ICU admission (OR 0.58) than both  
242 neither pregnant nor puerperal women and puerperal women. It should be mentioned that the two  
243 studies are not comparable, given that the Mexican study, on the one hand, included women who  
244 were not hospitalized and, on the other hand, divided reproductive age women into only two  
245 groups, pregnant and nonpregnant.

Our study has the following strong points: 1) the use of a national database with a large sample size number and no duplicates; 2) patients who were hospitalized due to severe acute respiratory syndrome, which was confirmed by the RT-PCR laboratory test; 3) discrimination between pregnant and puerperal women for a more accurate analysis of the obstetric population; 4) the use of paired comparison analysis through propensity score matching, which allowed adjustments for the demographic data and comorbidities to evaluate symptoms and outcomes.

As study limitations, a comparison with those infected with COVID-19 in the general population could not be made because only hospitalized cases with SARS and deaths are notified, and bias introduced by missing variables cannot be eliminated.

In the present study, the death risk of each comorbidity was identified separately for the three groups of women: pregnant, puerperal, and neither pregnant nor puerperal. This enabled the use of ORs included in the risk calculations for the COVID-19 progression at hospital admission.

Since puerperal women were at a higher risk for the most severe outcomes (need for ICU, use of invasive ventilatory support, and death), the fact that pregnancy is over must not underestimate the severity risks. Thus, in those cases in which the SARS-CoV-2 infection is acquired at the end of pregnancy, the delivery should be considered only after overcoming the disease. When it is acquired during the puerperal period, health professionals should remain alert to the severity-related risks. It would be ideal if all women were vaccinated to minimize the risks of SARS-CoV-2 infection and if they adhered to protection measures to prevent contamination by the virus.

As puerperal turned out to be a higher risk group than pregnant women among those hospitalized due to COVID-19, we need more studies comparing these groups. Furthermore, it should be considered that childbirth might influence the progression of COVID-19.

## **Data availability statement**

270 The data that support the findings of this study are available in GitHub repository at  
 271 [https://github.com/observatorioobstetrico/paper\\_covid19\\_groups](https://github.com/observatorioobstetrico/paper_covid19_groups). These data were derived from  
 272 the following resources available in the public domain:  
 273 <https://opendatasus.saude.gov.br/dataset/bd-srag-2020> obtained on January 11, 2021.

274

## 275 Acknowledgments

276 This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-027961].  
 277 Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License  
 278 has already been assigned to the Author Accepted Manuscript version that might arise from this  
 279 submission.

280

## 281 References

- 282 1. World Health Organization. WHO Director-General's opening remarks at the media briefing on  
 283 COVID-19 - 11 March 2020. Available from: [https://www.who.int/director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
 284 [general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
 285 [19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
- 286 2. WHO COVID-19 Dashboard [Internet]. Geneva: World Health Organization, 2021 - [cited 2021  
 287 Jun 28]. Available from: <https://covid19.who.int/>
- 288 3. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine  
 289 vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective  
 290 review of medical records. *Lancet*. 2020;395(10226):809-815.
- 291 4. Mullins E, Evans D, Viner RM, O'Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid  
 292 review. *Ultrasound Obstet Gynecol*. 2020;55(5):586-592.

- 293 5. Kasraeian M, Zare M, Vafaei H, Asadi N, Faraji A, Bazrafshan K, et al. COVID-19 pneumonia and  
294 pregnancy; a systematic review and meta-analysis. *J Matern Fetal Neonatal Med.* 2020;1-8.
- 295 6. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review  
296 of 108 pregnancies. *Acta ObstetGynecolScand.* 2020;99(7):823-829.
- 297 7. Di Toro F, Gjoka M, Di Lorenzo G, De Santo D, De Seta F, Maso G, et al. Impact of COVID-19 on  
298 maternal and neonatal outcomes: a systematic review and meta-analysis. *Clin Microbiol Infect.*  
299 2021;27(1):36-46.
- 300 8. Elshafeey F, Magdi R, Hindi N, Elshebiny M, Farrag N, Mahdy S, et al. A systematic scoping review  
301 of COVID-19 during pregnancy and childbirth. *Int J Gynaecol Obstet.* 2020;150(1):47-52.
- 302 9. Huntley BJF, Huntley ES, Di Mascio D, Chen T, Berghella V, Chauhan SP. Rates of Maternal and  
303 Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute  
304 Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. *Obstet Gynecol.*  
305 2020;136(2):303-312.
- 306 10. Sentilhes L, De Marcillac F, Jouffrieau C, Kuhn P, Thuet V, Hansmann Y, et al. Coronavirus  
307 disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. *Am J Obstet*  
308 *Gynecol.* 2020;223(6):914.e1-914.e15.
- 309 11. Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, El Hachem L, et al. Are clinical outcomes  
310 worse for pregnant women at  $\geq 20$  weeks' gestation infected with coronavirus disease 2019? A  
311 multicenter case-control study with propensity score matching. *Am J Obstet Gynecol.*  
312 2020;223(5):764-768.
- 313 12. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk  
314 factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living  
315 systematic review and meta-analysis. *BMJ.* 2020;370:m3320.



- 316 13. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics  
317 of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by  
318 Pregnancy Status - United States, January 22-October 3, 2020. *MMWR Morb Mortal Wkly Rep*.  
319 2020;69(44):1641-1647.
- 320 14. Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, Torres-Torres J, Espino Y Sosa S, et al. Pregnant  
321 women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score  
322 matched analysis of a nationwide prospective cohort (COV19Mx). *Ultrasound Obstet Gynecol*.  
323 2021;57(2):224-231.
- 324 15. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and outcomes  
325 of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national  
326 population-based cohort study. *BMJ*. 2020;369:m2107.
- 327 16. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian SE, et al. Maternal  
328 death due to COVID-19. *Am J Obstet Gynecol*. 2020;223(1):109.e1-109.e16.
- 329 17. Vallejo V, Ilagan JG. A Postpartum Death Due to Coronavirus Disease 2019 (COVID-19) in the  
330 United States. *ObstetGynecol*. 2020;136(1):52-55.
- 331 18. Lumbreras-Marquez MI, Campos-Zamora M, Lizaola-Diaz de Leon H, Farber MK. Maternal  
332 mortality from COVID-19 in Mexico. *Int J Gynaecol Obstet*. 2020;150(2):266-267.
- 333 19. Kayem G, Lecarpentier E, Deruelle P, Bretelle F, Azria E, Blanc J, et al. A snapshot of the Covid-19  
334 pandemic among pregnant women in France. *J GynecolObstet Hum Reprod*. 2020;49(7):101826.
- 335 20. Takemoto MLS, Menezes MO, Andreucci CB, Nakamura-Pereira M, Amorim MMR, Katz L, et al.  
336 The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting. *Int J Gynaecol Obstet*.  
337 2020;151(1):154-156.

- 338 21. Menezes MO, Takemoto MLS, Nakamura-Pereira M, Katz L, Amorim MMR, Salgado HO, et al.  
339 Risk factors for adverse outcomes among pregnant and postpartum women with acute respiratory  
340 distress syndrome due to COVID-19 in Brazil. *Int J Gynaecol Obstet.* 2020;151(3):415-423.
- 341 22. Amorim MMR, Soligo Takemoto ML, Fonseca EBD. Maternal deaths with coronavirus disease  
342 2019: a different outcome from low- to middle-resource countries? *Am J Obstet Gynecol.*  
343 2020;223(2):298-299.
- 344 23. Takemoto M, Menezes MO, Andreucci CB, Knobel R, Sousa L, Katz L, et al. Clinical characteristics  
345 and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance  
346 database analysis. *BJOG.* 2020;127(13):1618-1626.
- 347 24. Brasil. Ministério da Saúde. Definição de Caso e Notificação. Available from:  
348 <https://www.gov.br/saude/pt-br/coronavirus/artigos/definicao-e-casos-suspeitos>. Retrieved  
349 04/04/2021.
- 350 25. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of  
351 Confounding in Observational Studies. *Multivariate Behav Res.* 2011;46(3):399-424.
- 352 26. R Core Team. R: A language and environment for statistical computing. R Foundation for  
353 Statistical Computing, Vienna, Austria, 2020. Version 4.0.3 [software]. 2020 Oct 10 [cited 2021 Jan  
354 15]. Available from: <https://www.r-project.org/>
- 355 27. Greifer N. WeightIt: Weighting for Covariate Balance in Observational Studies. R package  
356 version 0.10.2 [software]. 2020 Sep 20 [cited 2021 Jan 15]. Available from: [https://cran.r-](https://cran.r-project.org/package=WeightIt)  
357 [project.org/package=WeightIt](https://cran.r-project.org/package=WeightIt)
- 358 28. Collin J, Byström E, Carnahan A, Ahrne M. Public Health Agency of Sweden's Brief Report:  
359 Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection  
360 in intensive care in Sweden. *Acta ObstetGynecol Scand.* 2020;99(7):819-822.

